Curative Biotechnology Inc(CUBT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.6
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CUBT

11/20/2026: CUBT (1-star) is currently NOT-A-BUY. Pass it for now.

Curative Biotechnology Inc is a development-stage biopharmaceutical company focused on discovering and advancing rare disease therapeutics across ophthalmology, infectious diseases, and neuro-oncology. Its main strengths lie in licensed collaborative assets like its metformin-based eye drop formulation for age-related macular degeneration. The primary investment story centers on potential clinical milestones and strategic partnerships that could unlock value from its early-stage pipeline. However, the company faces substantial risks, including high clinical development uncertainty, minimal revenues, and heavy reliance on external micro-cap financing. This stock is best suited for speculative risk-tolerant investors who should closely monitor upcoming clinical trial updates and regulatory patent progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks consistent revenue growth or commercial product expansion at this development stage.
Momentum investorStrong fit while signal remains positiveLow market capitalization and thin float can trigger sharp price movements during news-driven momentum phases.
Value investorWeak fitFundamental valuation metrics are difficult to apply given negative earnings and lack of stable cash flows.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for research.
Low-risk investorWeak fitHigh clinical, financial, and stock price volatility make this an unsuitable asset for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThin trading volume on the OTC market frequently results in sharp daily price swings.
Valuation riskHighPricing is largely speculative due to the absence of meaningful commercial revenues.
Competition risk (biopharmaceutical incumbents)HighWell-capitalized pharmaceutical rivals heavily dominate the target therapeutic indications.
Business qualityLowThe business remains pre-revenue with unproven clinical-stage assets.
Dividend incomeLow / noneNo dividend yield or income generation is provided to shareholders.
Execution riskHighSuccess relies entirely on navigating complex clinical trials, patents, and regulatory processes.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.91M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 1.3K shares
Beta 1.49
52 Weeks Range 0.45 - 1.99
Updated Date 11/20/2026
52 Weeks Range 0.45 - 1.99
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.35

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -84.23%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CUBT receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
CUBT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+36.5%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
CUBT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is CUBT's strongest growth driver at +36.5% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+15.0%, solid) is also solid, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.0% (soft) and 92.0% of outstanding shares are publicly tradable (strong). Insider ownership is only 0.03%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
CUBT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CUBT has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Research & LicensingFuture potential commercialization, milestone payments, or sub-licensing royalties from pipeline assets like Metformin Reformulation and IMT504.The company currently does not generate significant product revenue and operates as a speculative research venture.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5.51M
Price to Sales(TTM) 158.53
Enterprise Value 5.51M
Price to Sales(TTM) 158.53
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.88
Shares Outstanding 8.89M
Shares Floating 8.18M
Shares Outstanding 8.89M
Shares Floating 8.18M
Percent Insiders 0.03
Percent Institutions -

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.